emeis Société anonyme

LSE:0NEX Stock Report

Market Cap: €908.6m

emeis Société anonyme Valuation

Is 0NEX undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

5/6

Valuation Score 5/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 0NEX when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: 0NEX (€5.44) is trading below our estimate of fair value (€84.9)

Significantly Below Fair Value: 0NEX is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 0NEX?

Key metric: As 0NEX is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for 0NEX. This is calculated by dividing 0NEX's market cap by their current earnings.
What is 0NEX's PE Ratio?
PE Ratio0.6x
Earnings€1.47b
Market Cap€908.56m

Price to Earnings Ratio vs Peers

How does 0NEX's PE Ratio compare to its peers?

The above table shows the PE ratio for 0NEX vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average40.8x
CVSG CVS Group
21.9x15.5%UK£572.5m
SPI Spire Healthcare Group
30.7x26.9%UK£868.5m
MDC Mediclinic International
21.9x10.7%UK£3.7b
CRW Craneware
89x24.3%UK£829.9m
0NEX emeis Société anonyme
0.6x-108.0%€865.7m

Price-To-Earnings vs Peers: 0NEX is good value based on its Price-To-Earnings Ratio (0.6x) compared to the peer average (47.2x).

Price to Earnings Ratio vs Industry

How does 0NEX's PE Ratio compare vs other companies in the European Healthcare Industry?

3 CompaniesPrice / EarningsEstimated GrowthMarket Cap
Industry Avg.18.8x23.3%
0NEX emeis Société anonyme
 0.6x-108.0%US$907.48m
0NEX 0.6xIndustry Avg. 18.8xNo. of Companies10PE01020304050+
3 CompaniesEstimated GrowthMarket Cap
Industry Avg.18.8x23.3%
0NEX emeis Société anonyme
 0.6x-108.0%US$907.48m
No more companies

Price-To-Earnings vs Industry: 0NEX is good value based on its Price-To-Earnings Ratio (0.6x) compared to the European Healthcare industry average (18.8x).

Price to Earnings Ratio vs Fair Ratio

What is 0NEX's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

0NEX PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio0.6x
Fair PE Ratio4.8x

Price-To-Earnings vs Fair Ratio: 0NEX is good value based on its Price-To-Earnings Ratio (0.6x) compared to the estimated Fair Price-To-Earnings Ratio (4.8x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst 0NEX forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
Current€5.44
€10.53
+93.5%
28.6%€14.00€7.20n/a4
Nov ’25€6.31
€11.63
+84.4%
23.0%€14.00€7.90n/a3
Oct ’25€5.51
€11,633.33
+211,223.0%
23.0%€14,000.00€7,900.00n/a3
Sep ’25€9.16
€11,633.33
+126,872.2%
23.0%€14,000.00€7,900.00n/a3
Aug ’25€10.29
€11,633.33
+112,919.8%
23.0%€14,000.00€7,900.00n/a3
Jul ’25€12.38
€11,725.00
+94,600.9%
24.7%€15,000.00€7,900.00n/a4
Jun ’25€12.52
€11,725.00
+93,543.9%
24.7%€15,000.00€7,900.00n/a4
May ’25€13.20
€10,975.00
+83,016.0%
20.7%€14,000.00€7,900.00n/a4
Apr ’25€10.75
€6,230.00
+57,871.3%
95.5%€14,000.00€20.00n/a4
Mar ’25€12.94
€3,640.00
+28,029.8%
123.9%€10,000.00€20.00n/a3
Feb ’25€13.80
€2,737.50
+19,737.0%
153.7%€10,000.00€20.00n/a4
Jan ’25€16.81
€2,737.50
+16,184.9%
153.7%€10,000.00€20.00n/a4
Dec ’24€17.42
€2,737.50
+15,614.7%
153.7%€10,000.00€20.00n/a4
Nov ’24€898.71
€3,910.00
+335.1%
117.1%€10,000.00€20.00€6.315
Oct ’24€1,472.11
€3,909.99
+165.6%
117.1%€10,000.00€20.00€5.515
Sep ’24€1,702.83
€3,909.99
+129.6%
117.1%€10,000.00€20.00€9.165
Aug ’24€1,750.07
€3,939.99
+125.1%
115.6%€10,000.00€30.02€10.295
Jul ’24€1,904.67
€4,005.97
+110.3%
112.3%€10,000.00€170.01€12.385
Jun ’24€1,858.75
€4,917.48
+164.6%
93.5%€10,000.00€170.01€12.524
May ’24€2,656.67
€5,561.99
+109.4%
76.7%€10,000.00€289.94€13.205
Apr ’24€2,070.99
€5,601.65
+170.5%
69.5%€10,000.00€289.94€10.756
Mar ’24€2,495.44
€10,944.27
+338.6%
124.0%€43,000.00€289.94€12.947
Feb ’24€6,167.13
€13,688.58
+122.0%
91.1%€43,000.00€4,000.00€13.807
Jan ’24€6,204.00
€17,165.00
+176.7%
86.5%€43,000.00€4,000.00€16.818
Dec ’23€6,756.76
€17,415.00
+157.7%
84.1%€43,000.00€5,799.97€17.428
Nov ’23€9,103.34
€25,928.56
+184.8%
56.1%€43,000.00€7,000.00€898.717

Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.

Discover undervalued companies

Elevance Health

US$94.5b

Operates as a health benefits company in the United States.

0HG8

US$401.36

7D

1.7%

1Y

-16.0%

Centene

US$31.0b

Operates as a healthcare enterprise that provides programs and services to under-insured and uninsured families, commercial organizations, and military families in the United States.

0HVB

US$60.77

7D

3.9%

1Y

-17.3%

Patterson Companies

US$1.9b

Engages in the distribution of dental and animal health products in the United States, the United Kingdom, and Canada.

0KGB

US$21.06

7D

-0.8%

1Y

-32.9%